Selegiline

Selegiline Brands ;

Brand Name	Manufacturer Name	Distributor	Drug Strength	Packaging	Formulation	Formulation Strength	Price
Selerin	Metro Limited.	Metro Limited	5mg	60	Tablet	per tablet	KES 800.00

Selegiline More Info
Mode Of Action	Selegiline is an irreversible inhibitor of monoamine oxidase type B (MAO B), which is involved in the oxidative deamination of dopamine in the brain. It is also thought to interfere with dopamine re-uptake at the synapse.
Drug Indication	Parkinsonism, (but not drug-induced extrapyramidal symptoms). Can be used alone or with levodopa.
Precautions	Elderly, angina, arrhythmias, psychosis, pregnancy, breast-feeding, impairment, poorly controlled hypertension, avoid in active ulceration, need to reduce the dose of L-dopa by 10-50% when concurrently administered.
Side Effects	GI disturbances, psychosis, sore throat, hypotension, skin reactions, vertigo, tremor, agitation, back pain, depression, sleep disturbance, muscle cramps, difficulty in passing urine.
Dosage	10mg in the morning or 5mg at breakfast and midday
Pregnancy Category	Category B2
Pregnancy Category Description	Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage. Studies in animals are inadequate or lacking but available data show no evi-dence of an increased occurrence of foetal damage.
Drug Category	DRUGS ACTING ON CNS
Drug Sub-Category	Rigidity and tremor controllers Dosing: Adult Parkinson’s disease: Capsule/tablet: 5 mg twice daily with breakfast and lunch Orally disintegrating tablet (Zelapar®): Initial 1.25 mg daily for at least 6 weeks; may increase to 2.5 mg daily based on clinical response (maximum: 2.5 mg daily) Depression: Transdermal (Emsam®): Initial: 6 mg/24 hours once daily; may titrate based on clinical response in increments of 3 mg/day every 2 weeks up to a maximum of 12 mg/24 hours Dosing: Pediatric ADHD (unlabeled use): Children and Adolescents: Oral: 5-15 mg/day (Jankovic, 1993) Dosing: Geriatric Parkinson's disease: Capsule/tablet: ≤5 mg/day (when combined with levodopa) is recommended by some clinicians to decrease the enhanced dopaminergic side effects (Olanow, 2001) Orally disintegrating tablet (Zelapar®): Refer to adult dosing Depression: Transdermal (Emsam®): 6 mg/24 hours Dosing: Renal Impairment Oral: Use caution, has not been studied. Transdermal: No adjustment required in patients with mild-to-moderate impairment. Dosing: Hepatic Impairment Oral: Use caution, has not been studied. Transdermal: No adjustment required in patients with mild-to-moderate impairment. Dosage Forms: U.S. Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Capsule, oral, as hydrochloride: 5 mg Eldepryl®: 5 mg Patch, transdermal: Emsam®: 6 mg/24 hours (30s) [20 cm2, total selegiline 20 mg] Emsam®: 9 mg/24 hours (30s) [30 cm2, total selegiline 30 mg] Emsam®: 12 mg/24 hours (30s) [40 cm2, total selegiline 40 mg] Tablet, oral, as hydrochloride: 5 mg Tablet, orally disintegrating, oral: Zelapar®: 1.25 mg [contains phenylalanine 1.25 mg/tablet; grapefruit flavor] Generic Equivalent Available: U.S. Yes: Capsule, tablet Administration Oral: Orally disintegrating tablet (Zelapar®): Take in morning before breakfast; place on top of tongue and allow to dissolve. Avoid food or liquid 5 minutes before and after administration. Topical: Transdermal (Emsam®): Apply to clean, dry, intact skin to the upper torso (below the neck and above the waist), upper thigh, or outer surface of the upper arm. Avoid exposure of application site to external heat source, which may increase the amount of drug absorbed. Apply at the same time each day and rotate application sites. Wash hands with soap and water after handling. Avoid touching the sticky side of the patch. Use Adjunct in the management of parkinsonian patients in which levodopa/carbidopa therapy is deteriorating (oral products); treatment of major depressive disorder (transdermal product) Use - Unlabeled/Investigational Early Parkinson's disease; attention-deficit/hyperactivity disorder (ADHD)